Sequrna

Sequrna is a Stockholm-based biotech firm that has developed a next-generation, thermostable RNase inhibitor, a critical reagent for RNA sequencing. Unlike traditional protein-based inhibitors, Sequrna's synthetic product is stable at room temperature, simplifying logistics, reducing costs, and enabling novel experimental protocols involving heat cycles. The company's technology addresses key pain points in genomics workflows, including batch effects and sensitivity, positioning it as an innovator in the research tools market for advanced genomics applications.

Synthetic, thermostable RNase inhibitor engineered for room-temperature stability and compatibility with demanding RNA-sequencing workflows, enabling novel protocols and reducing batch effects.

Sequrna competes in the life science reagents market against giants like Thermo Fisher Scientific and New England Biolabs, which offer standard recombinant RNase inhibitors. Its key differentiators are thermostability, batch consistency, and room-temperature logistics. It also competes with other niche players developing alternative RNase inactivation methods, but its synthetic chemistry approach is distinctive.